Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of intravesical disitamab vedotin in HER2-expressing high-risk non-muscle-invasive bladder cancer
CTR20241297Phase 2Active
- Sponsor
- RemeGen
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dapoxetine and disitamab vedotin in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by RemeGen. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Jun 2024; status: active.
02
Drugs
dapoxetinedisitamab vedotin
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20241297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241297.